N/A
N=585
An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes
Eyelash Hypotrichosis
Bottom Line
View on ClinicalTrials.gov: NCT01623479 ↗Enrolled (actual)
585
Serious AEs
0.0%
Results posted
Sep 2012
Primary outcome: Primary: Percentage of Subjects Satisfied With Latisse® — 92.48 Percentage of Subjects
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- bimatoprost 0.03% (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Sep 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Subjects Satisfied With Latisse® |
92.48 | — |
| SECONDARY Number of Applications of Latisse® Per Week |
6.69 | — |
| SECONDARY Percentage of Subjects Satisfied Wtih Their Eyelashes |
79.81 | — |
Summary
This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.
Eligibility Criteria
Inclusion Criteria
- Hypotrichosis of the eyelashes
- Using bimatoprost ophthalmic solution 0.03% (Latisse®) for at least 12 months
Exclusion Criteria
- Use of any over-the-counter medication(s) for eyelash growth
Data sourced from ClinicalTrials.gov (NCT01623479). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.